Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
30 Results for "
Inflammatory Response Syndrome
" in MedChemExpress (MCE) Product Catalog:
Products (30)
30 Results for "Inflammatory Response Syndrome" in MCE Product Catalog:
9
9 Publications Verification
Target:
Research Areas:
RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting
protein 1 (RIP1) with an IC50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome .
5
Category:
Human Gut Microbiota Metabolites Plant Polysaccharides Cichorium intybus L. Extract Metabolic Disease Compositae/Asteraceae Extract Endogenous metabolite Disease Research Fields Saccharides
Target:
3
Category:
Rutaceae Extract Citrus × aurantium Linnaeus Extract Endogenous metabolite Alkaloids Plant Monophenols Other Alkaloids Other Diseases Phenols Disease Research Fields
Target:
1
1 Cited Publications
Target:
Research Areas:
PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis .
Category:
Plant Polysaccharides Other Diseases Zea mays L. Extract Disease Research Fields Saccharides Poaceae/Gramineae Extract
Target:
Target:
Research Areas:
AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (Ki=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .
Cat. No.: HY-P99928
CAS No.: 2574508-57-7
Synonyms: MK-7110; CD24 Fc
Target:
Research Areas:
Efprezimod alfa (MK-7110; CD24 Fc) is a humanized CD24-Fc fusion protein. Efprezimod alfa enhances the interaction between CD24 and Siglec-10, thereby regulating the response of innate immune cells to damage-associated molecular patterns, inhibiting the activation of antigen-presenting cells and subsequent inflammatory responses. Efprezimod alfa is applicable to the research of acute graft-versus-host disease and acquired immunodeficiency syndrome .
Cat. No.: HY-174140
CAS No.: 932973-77-8
Target:
Research Areas:
VU0514009 is a competitive chemokine-like receptor 1 (CMKLR1) antagonist (EC50=2 nM). VU0514009 prevents chemerin-9-induced arrestin recruitment and receptor internalization, significantly reducing Ca 2+ flux response in HEK293 cells. VU0514009 is promising for research of inflammatory diseases and metabolic syndrome .
Synonyms: C-PAF
Research Areas:
Carbamyl-PAF (C-PAF) is a metabolically stable platelet-activating factor analog and PAF receptor agonist that activates G protein-coupled PAF receptors, triggering calcium mobilization, NF-κB activation, and downstream signaling, thereby inducing neutrophil recruitment, inflammatory responses, and ROS generation. Carbamyl-PAF is used in research on obesity, pulmonary inflammation, Zellweger syndrome, and non-melanoma skin cancer .
Target:
Research Areas:
RIPK1-IN-19 is a selective RIPK1 inhibitor (IC50=15 nM). RIPK1-IN-19 does not show obvious activity against RIPK2, RIPK3, and RIPK4. RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases .
Cat. No.: HY-155801
CAS No.: 216014-14-1
Research Areas:
Cardiovascular Disease Infection Neurological Disease Inflammation/Immunology Cancer
CRX 527 is a TLR4 agonist. CRX 527 activates the MyD88-dependent, TRIF-dependent, and TRAF6/NF-κB signaling pathways downstream of TLR4, mimics lipid A, and regulates antigen processing and presentation by dendritic cells. CRX 527 stimulates innate immune responses and enhances vaccine efficacy. CRX 527 maintains the structural integrity of hematopoietic tissues, spleen and intestine, alleviates radiation-induced damage, preserves intestinal homeostasis, and inhibits apoptosis, inflammatory responses, oxidative stress and DNA damage. CRX 527 can be used in the research of acute radiation syndrome, melanoma, HPV-related tumors and intracerebral hemorrhage .
Cat. No.: HY-178163
Research Areas:
Zharp1-163 is a dual inhibitor of ferroptosis and necroptosis. Zharp1-163 effectively blocks ferroptosis by reducing reactive oxygen species (ROS) levels and inhibits necroptosis by potently and selectively targeting RIPK1 kinase activity (KD = 240 nM; IC50 = 406.1 nM). Zharp1-163 inhibits the cellular activation of RIPK1, RIPK3 and MLKL in response to necroptotic stimulation. Zharp1-163 markedly attenuates TNF-α (HY-P1875)-induced systemic inflammatory syndrome, including the prevention of TNF-α-induced mortality and hypothermia in mice. Zharp1-163 significantly alleviates acute kidney injury associated with both necroptosis and ferroptosis in models induced by Cisplatin (HY-17394) and ischemia-reperfusion. Zharp1-163 can be used for the study of diseases associated with cell death pathways, such as kidney disease .
Cat. No.: HY-178762S
CAS No.: 3103886-96-7
Cat. No.: HY-161682
CAS No.: 2654791-96-3
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
GPR84 antagonist 9 is an orally active GPR84 antagonist with an IC50 value of 12 nM. By antagonizing the GPR84 receptor, GPR84 antagonist 9 blocks immune cell migration, M1 polarization, and the release of inflammatory factors (IL1β/TNFα) induced by medium-chain free fatty acids (MCFFAs) and other substances, thereby comprehensively inhibiting inflammatory and fibrotic responses. GPR84 antagonist 9 can be used in the research of inflammation-driven pain disorders, including neuropathic pain disorders, Fabry disease, gout, and bladder pain syndrome .
Research Areas:
RIPK1-IN-17 is an orally active, selective RIPK1 inhibitor (Kd = 17 nM) and shows no significant inhibition to RIPK3. RIPK1-IN-17 specifically inhibits necroptosis rather than apoptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation. RIPK1-IN-17 protects mice from hypothermia and death. RIPK1-IN-17 can be used for the study of necroptosis-related diseases such as inflammatory response syndrome (SIRS) .
Cat. No.: HY-14909R
CAS No.: 218600-44-3
Synonyms: CDDO (Standard); RTA 401 (Standard)
Research Areas:
Bardoxolone (Standard) is the analytical standard of Bardoxolone (HY-14909). This product is intended for research and analytical applications. Bardoxolone is an orally active activator of nuclear regulatory factor (NRf-2) and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 μM in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 μM by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome (SIRS), and cerebral ischemia-reperfusion injury .
Synonyms: 1,4-β-D-Xylobiose (Standard); 1,4-D-Xylobiose (Standard)
Target:
Cat. No.: HY-N13798
CAS No.: 138870-97-0
Cat. No.: HY-149052
CAS No.: 2919801-86-6
Research Areas:
SZM-1209 is an orally active, potent and specific RIPK1 inhibitor, with a Kd of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC50=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects .
Cat. No.: HY-156367
CAS No.: 2561431-77-2
Target:
Research Areas:
RIPK1-IN-16 is an orally active and potent inhibitor of RIPK1. RIPK1-IN-16 inhibits excessive inflammation by blocking RIPK1-mediated necroptosis in vivo. RIPK1-IN-16 protects mouse from TNF-induced systemic inflammatory response syndrome and sepsis .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
